Fig. 4: Response rates over time in the ITT population.

Response rates by 6, 12, 18, 24, and 30 months in the ITT population. ITT intent-to-treat, ORR overall response rate, CR complete response, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, PR partial response, VGPR very good partial response, sCR stringent complete response.